June 6, 2018
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3030
Washington, D.C. 20549
| Attn: | Amanda Ravitz |
Tom Jones
| Re: | Inovio Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed May 25, 2018
File No. 333-225233
Acceleration Request
Requested Date: June 8, 2018
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-225233), as amended (the “Registration Statement”), to become effective on June 8, 2018, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the staff (the “Staff”). The Registrant hereby authorizes each of Brian Leaf, Daniel Goldberg and Jeffrey Libson of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Brian Leaf of Cooley LLP at (703) 456-8053.
[Signature page follows]
6769 Mesa Ridge Road
San Diego, CA 92121
Phone: (858) 597-6006
Fax: (858) 404-1392
Very truly yours,
Inovio Pharmaceuticals, Inc.
By: /s/ Peter Kies
Peter Kies
Chief Financial Officer
| cc: | Brian Leaf, Cooley LLP |
Daniel Goldberg, Cooley LLP
Jeffrey Libson, Cooley LLP
Darah Protas, Cooley LLP
6769 Mesa Ridge Road
San Diego, CA 92121
Phone: (858) 597-6006
Fax: (858) 404-1392